Document:

AMENDMENT
      NO. 1 TO

    2006
      INCENTIVE STOCK PLAN

    

    This
      Amendment No. 1 hereby amends the Neuro-Hitech, Inc. 2006 Incentive Stock Plan,
      effective as of October 31, 2006 (collectively, the “Plan”).
      This
      Amendment No. 1 is adopted as of October 31, 2006.

    

    The
      first
      sentence of Section 4 of the Plan is hereby amended and restated in its entirety
      as follows:

    

    Subject
      to adjustment as provided in Section 8 hereof, a total of 1,200,000 shares
      of
      the Company’s Common Stock, par value $0.001 per share (the “Stock”), shall be
      subject to the Plan.

    

    The
      foregoing Amendment No. 1 to the Plan was adopted by the Board of Directors
      of
      Neuro-Hitech, Inc. pursuant to a unanimous written consent in lieu of a special
      meeting of the Board of Directors as of October 31, 2006.AMENDMENT
      NO. 2 TO

    2006
      INCENTIVE STOCK PLAN

    

    This
      Amendment No. 2 hereby further amends the Neuro-Hitech, Inc. 2006 Incentive
      Stock Plan, effective as of November 28, 2006, as previously amended by
      Amendment No. 1 adopted as of October 31, 2006 (collectively, the “Plan”).
      This
      Amendment No. 2 is adopted as of November 28, 2006.

    

    The
      first
      sentence of Section 4 of the Plan is hereby amended and restated in its entirety
      as follows:

    

    Subject
      to adjustment as provided in Section 8 hereof, a total of 1,350,000 shares
      of
      the Company’s Common Stock, par value $0.001 per share (the “Stock”), shall be
      subject to the Plan.

    

    Section
      5(b) of the Plan is hereby amended and restated in its entirety as
      follows:

    

    OPTION
      TERM. The term of each Option shall be fixed by the Committee, provided,
      however, no Incentive Option shall be exercisable more than ten years after
      the
      date such Option is granted and in the case of an Incentive Option granted
      to an
      Optionee who, at the time such Incentive Option is granted, owns (within the
      meaning of Section 424(d) of the Code) more than 10% of the total combined
      voting power of all classes of stock of the Company or of any Subsidiary, no
      such Incentive Option shall be exercisable more than five years after the date
      such Incentive Option is granted.

    

    The
      foregoing Amendment No. 2 to the Plan was adopted by the Board of Directors
      of
      Neuro-Hitech, Inc. pursuant to a unanimous written consent in lieu of a special
      meeting of the Board of Directors as of November 28, 2006.CONSULTANT
      AGREEMENT

    

    This
      Agreement (the “Agreement”) is made in New York, New York as of November 29,
      2006 by and between Neuro-Hitech, Inc., One Penn Plaza, Suite 1503, New York,
      New York 10119 (“NHI”), and D.F. Weaver Medical, Inc., with a principle place of
      business at 11 Falcon Pl, Halifax, Nova Scotia B3M 3R4, Donald F. Weaver,
      Principal Consultant (“Consultant”). The Agreement shall become effective as of
      the closing of the Merger (defined below).

    

    Consultant
      has previously entered into a Consultant Agreement with Q-RNA, Inc. (the “Prior
      Agreement”). NHI is acquiring Q-RNA, Inc. by merger (the “Merger”), and in
      connection with the closing of the Merger NHI desires to retain the Consultant
      to perform services for NHI. Consultant is willing to perform such services
      pursuant to the terms and conditions hereof.

    

    THEREFORE,
      NHI
      and
      Consultant hereby agree as follows:

    

    1. Engagement.
      NHI
      retains Consultant to perform services outlined and summarized in the work
      Summary, attached hereto as an Appendix A, and to the extent the Appendix A
      is
      consistent with the terms of this agreement, it is incorporated herein.
      Consultant hereby accepts such engagement and shall perform such services in
      a
      timely manner under the general supervision of NHI. The Consultant shall take
      general direction from the individual or individuals identified as contact
      persons in the Appendix A, or other designated NHI employee(s). Services will
      be
      performed by Consultant at NHI facilities or at such place as is designated
      by
      NHI. The services are to be performed during normal business hours, unless
      otherwise specified.

    

    2. Compensation
      and Hours.
      

    

    (a) In
      full
      consideration of the completion of work or services under this agreement, NHI
      or
      its appointed agent, shall:

    

    (i)
      pay
      Consultant a fee, in accordance with the payment schedule, if any, specified
      in
      Appendix A. Such fee shall cover all ancillary expenses, such as office supplies
      and secretarial expenses. Consultant shall submit a Statement of Services to
      NHI
      at the end of each month (or such other period as may be agreed to by the
      parties) setting forth the tasks performed, the person(s) for whom such tasks
      were performed, and specifying the fees due with respect thereto. In addition
      and as appropriate Consultant may be required to submit supporting documents.
      NHI agrees to remit payment to Consultant within thirty (30) days of receipt
      of
      such statement, unless otherwise agreed.

    

    (ii)
      grant Consultant an option to purchase 500,000 shares of NHI’s common stock upon
      the closing of the Merger pursuant to the Company’s stock option plan. Such
      option shall have an exercise price equal to the closing price for the NHI
      common stock as reported on the OTC Bulletin Board on the business day prior
      to
      the closing of the Merger, shall have a term of fifteeen years, shall include
      the vesting terms set forth in Appendix B and otherwise shall be in the form
      of
      Appendix B. 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    (b) In
      a
      typical year, it is expected that NHI would require two (2) days per quarter
      or
      eight (8) days per year of Consultant’s time. However, NHI will limit its
      requests for Consultant’s services to a maximum of no more than twenty (20) days
      per year.

    

    3. Term,
      Notice and Termination.
      The
      term
      of this Agreement shall begin on the Effective Date and shall continue until
      the
      Termination Date specified in the Appendix A. This Agreement may be terminated
      by NHI, at any time upon reasonable notice, not to exceed thirty days. This
      Agreement may be terminated by Consultant in the event of a breach of a material
      term of the Agreement by NHI or by written notification as stipulated in
      Appendix A. This Agreement may be terminated immediately if mutually agreed
      upon
      by both the Consultant and NHI. Termination of the Agreement does not relieve
      Consultant of obligations under Paragraphs 5, 6 and 7. In the event of
      termination by NHI, NHI shall reimburse Consultant for non-cancellable charges
      and expenses incurred by Consultant. In no event shall NHI be liable for
      indirect, consequential or punitive damages.

    

    4. Status.
      Consultant
      acknowledges and agrees that as a contractor for NHI, Consultant is not
      considered an employee of NHI under any federal, state, or local law and is
      not
      entitled to any benefits or privileges given or extended by NHI to its
      employees.

    

    5. No
      Conflict.
      Any
      activities the Consultant undertakes with third parties shall not conflict
      with
      work performed for NHI. Consultant represents and warrants that Consultant
      has
      authority to make any disclosure of information which NHI receives
      hereunder.

    

    6. Confidentiality.
      During
      the term of this Agreement certain proprietary information may be acquired
      by
      Consultant, and during the term of the Prior Agreement certain proprietary
      information may have been acquired by Consultant (collectively, the
“Information”). The Information is valuable to the Consultant and allows the
      Consultant to perform services or bid on services to be performed for NHI.
      Consultant shall use the Information solely for the purposes set forth herein
      and shall not disclose the Information, or any part thereof, to any third party
      except to the extent necessary to perform services for NHI. All Information,
      including but not limited to, documents, drawings, technical information,
      sketches, designs, business information, employee and customer lists, vendors,
      suppliers, distributors, and marketing plans, furnished to Consultant by NHI
      or
      Q-RNA shall remain the property of NHI and shall be returned to NHI promptly
      at
      its request, together with any and all copies made thereof by
      Consultant.

    

    No
      obligation shall be imposed on Consultant with respect to any Information which:
      

    

    (a) at
      or before the time of disclosure is, or becomes through no act or omission
      of
      Consultant, part of the public domain;

    

    (b)
      was
      known, as shown by independently verifiable written records, to Consultant
      at or
      prior to disclosure to Consultant, provided that such knowledge was not gained
      from third parties through breach of confidentiality obligation;

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    (c)
      is
      subsequently disclosed to Consultant by a third party having no obligation
      of
      confidentiality with respect to the Information; or

    

    (d)
      is
      required to be disclosed by any governmental, judicial or administrative
      proceeding, provided that Consultant will take reasonable precautions to notify
      NHI of such disclosure prior to the event.

    

    7. Disclosure,
      Assignment of Intellectual Property.
      In
      consideration of the disclosure of certain proprietary information by NHI to
      Consultant, Consultant agrees, during the term of this Agreement and thereafter,
      to promptly report and disclose to a representative of NHI, all inventions,
      ideas, technical improvements, and other valuable information, and all literary,
      artistic, compositional works, industry reports, programs, manuals, tapes,
      card
      decks, blueprints, listings, discussions and other programming documentation
      (hereinafter collectively termed “Intellectual Property”) made or conceived in
      the performance of work or services under this Agreement. All such Intellectual
      Property shall be owned exclusively by NHI, as a work made for hire in the
      case
      of copyrightable material, NHI shall own the material and the copyrights.
      Consultant shall assign to NHI Consultant’s entire interest in such Intellectual
      Property, and upon NHI’s request, shall execute and deliver all papers and
      documents which NHI may deem appropriate in order to effect such assignment.
      Consultant will assist NHI in the drafting and filing of all papers and
      applications reasonably necessary for perfection of NHI’s right in such
      Intellectual Property. Consultant will be compensated at the specified hourly
      rate for such assistance. There shall be no restriction on NHI’s right to use,
      disclose, or otherwise deal with the information, data or services provided
      by
      Consultant.

    

    For
      clarification, any Intellectual Property developed by or under the direction
      of
      Dr. Donald Weaver, under a Research Agreement between either Queen’s University
      or Dalhousie University and NHI, shall be owned and managed in accordance with
      the terms of that Research Agreement. The Research Agreement will take
      precedence should there be conflict between this Agreement and the Research
      Agreement. For further clarification, any Intellectual Property that is
      dominated by Intellectual Property created during this Agreement which is
      subject of a License Agreement between Parteq Innovations and NHI or that falls
      under the scope of Intellectual Property licensed by Parteq to NHI, will be
      owned by Queen’s University or Dalhousie University as the case may be, and made
      available under the existing license agreement. 

    

    8. Safety
      Requirements.
      Consultant
      shall take all necessary and reasonable precautions to prevent the occurrence
      of
      any injury to persons or property during the performance of services hereunder,
      including those precautions that NHI personnel direct or impose. NHI shall
      have
      no liability to Consultant, and Consultant shall hold NHI harmless in respect
      to
      Consultant, Consultant employee or third party injuries, deaths, losses and
      damages which occur as a result of Consultant performing under this
      Agreement.

    

    9. Compliance
      with Laws and Regulations.
      Consultant
      shall comply with applicable provisions of Federal U.S.A., Canadian, State,
      Provincial and Local laws and regulations in the performance of services
      hereunder, including but not limited to, the laws of the United States and
      Canada relating to export, the Fair Labor Standard Act and
      Non-discrimination.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    10. NHI’s
      Rights to Proceed.
      NHI
      shall
      have the right to proceed directly against Consultant for any breach of the
      Consultant’s obligations under Paragraphs 5, 6 and 7. Consultant acknowledges
      that a breach of Consultant’s obligations under Paragraphs 5, 6 and 7 will cause
      NHI irreparable harm and entitles NHI to immediate injunctive
      relief.

    

    11. Delivery
      Schedule.
      Time
      is
      of the essence. It is Consultant’s responsibility to comply with times for the
      delivery of services, documents and information. NHI’s failure to deliver
      services, documents and information on time shall add to any other delays.
      Consultant’s failure to deliver services and/or product in accordance with the
      delivery schedule shall allow NHI to terminate immediately without
      notice.

    

    12. Non-Assignment.
      Assignment
      of this Agreement or any interest herein or any payment due or to become due
      hereunder, without the written consent of the other party, shall be void and
      of
      no effect and may, at the option of the non-assigning party, render this
      Agreement void.

    

    13. Waiver
      of Liability.
      NHI
      will
      not be liable to Consultant for any personal injuries or property damage
      sustained by Consultant in performance of services hereunder. Consultant shall
      hold NHI harmless from all liability for personal injuries or property damage
      directly related to the performance of contracted services unless NHI is
      negligent.

    

    14. Miscellaneous.
      This
      Agreement represents the entire understanding of the parties, and no other
      prior
      or contemporaneous writings will be considered part of this Agreement. In
      particular, this Agreement supersedes the Prior Agreement, except to the extent
      that Sections 7, 8, 10 and 13 of the Prior Agreement continue in effect by
      their
      terms. Modifications of this Agreement must be made in writing, and signed
      by
      the party against whom enforcement is sought. This Agreement shall be construed
      under the laws of the state of New York, New York, U.S.A. If any of the
      provisions of this Agreement are found to be unenforceable, void, or illegal,
      the surviving provisions shall remain valid and in effect. 

    

    In
      Witness Whereof the
      Parties have executed this Agreement in duplicate counterparts as of the date
      first written above.

     

    
      	Consultant	 	 
	 	 
	D.F. Weaver Medical, Inc.	 
	 
By: 
              /s/ Donald F. Weaver	 
 	 
 
	
              
                

              

              Donald
                F. Weaver, M.D., Ph.D.

            	  	 

    

    

    
      	Neuro-Hitech,
              Inc.	 	 
	 	 
	 
By: 
              /s/ Reuben Seltzer	 
 	 
 
	
              
                

              

              Chief
                Executive Officer

            	  	 
	 	 

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Appendix
      A

     

    Consultant:
      The
      Consultant’s services shall be furnished by Donald
      F.
      Weaver, M.D., Ph.D.

    

    Project
      Effective Date: The
      project effective date shall be the Effective Date of the Agreement to which
      this Appendix is attached.

     

    Project
      Term, Renewal and Termination Date: Project
      term shall be one year from Effective Date and renewable annually and
      automatically unless one party indicates a desire to terminate the relationship.
      Termination notification shall be given by Consultant 30 days prior to
      Termination Date.

     

    Payment
      to Contractor: The
      Company shall pay Consultant US$1,000 per day of consulting, pro rata as
      appropriate for services actually performed. Consultant shall receive
      instruction and direction as to the subject matter and time of the work to
      be
      performed. Reasonable and customary out of pocket expenses incurred by the
      Consultant shall be reimbursed. Expenses in amounts greater than US$500 require
      prior approval of NHI.

     

    Specify
      support documentation necessary:
      Consultant shall submit one or more invoices for work actually performed. Such
      invoices shall describe the services performed and the time charges associated
      with such work.

     

    Contact
      persons (NHI):

     

    Reuben
      Seltzer & L. William McIntosh - for administrative, licensing, and other
      business matters

     

    Summary
      of work to be performed: To
      serve
      as a member on NHI’s Scientific Advisory Board (SAB) and on an “as requested”
basis consult with NHI on matters pertaining to the research and development
      of
      products owned or licensed by NHI. In addition, to serve as the overall
      coordinator and administrator of any formal licensing, sponsored research or
      other agreements as executed by NHI with Queens University, PARTEQ Innovations
      and Dalhousie University. NOTE:
      Any
      formal licensing, sponsored research agreements for and between NHI and Dr.
      Donald F. Weaver, Queens University, PARTEQ Innovations and Dalhousie University
      shall supersede any provisions of this Agreement.

     

    
      	Approved:	 	 	 
	 	 	 	 
	D.F. Weaver Medical,
              Inc.	 	 	 
	 	 	 	 
	 	 	 	 
	By: 
/s/
              Donald F. Weaver	 	 	 
	
              
                

              

              Donald
                F. Weaver, M.D., Ph.D.

            	 	 	
            
	 	 	 	
            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Appendix
      B

     

    Vesting
      Term: 

    

    
      	
              Milestone

            	 	
              Per
                Cent

            	 	 	 
	 	 	 	 	 	 
	
              PTO
                allows/issues first of anti-amyloid patent applications

            	 	 	
              15.0

            	
              %

            	 	
              75,000
                

            	 
	 	 	 	 	 	 	 	 
	
              IND
                for any anti-amyloid compound approved by FDA

            	 	 	
              15.0

            	
              %

            	 	
              75,000
                

            	 
	 	 	 	 	 	 	 	 
	
              Completion
                of Phase II trial of first anti-amyloid compound

            	 	 	
              15.0

            	
              %

            	 	
              75,000
                

            	 
	 	 	 	 	 	 	 	 
	
              Completion
                of Phase III trial of first anti-amyloid compound

            	 	 	
              15.0

            	
              %

            	 	
              75,000
                

            	 
	 	 	 	 	 	 	 	 
	
              For
                each successful year completed of Sponsored Research
                Agreement

            	 	 	 	 	 	 	 
	
                  
                Year 1 July 2005 - June 2006

            	 	 	
              10.0

            	
              %

            	 	
              50,000
                

            	 
	
                  
                Year 2 July 2006 - June 2007

            	 	 	
              10.0

            	
              %

            	 	
              50,000
                

            	 
	
                  
                Year 3 July 2007 - June 2008

            	 	 	
              10.0

            	
              %

            	 	
              50,000
                

            	 
	
                  
                Year 4 July 2008 - June 2009

            	 	 	
              10.0

            	
              %

            	 	
              50,000
                

            	 
	 	 	 	 	 	 	 	 
	
              TOTAL

            	 	 	
              100.0

            	
              %

            	 	 	 

    

     

    
      	
              Approved:

            	 	 	 
	 	 	 	 
	D.F. Weaver Medical,
              Inc.	 	 	 
	 	 	 	 
	 	 	 	 
	By: 
              /s/ Donald F. Weaver	 	 	 
	
              
                

              

              Donald
                F. Weaver, M.D., Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]